VIDA mRNA: Cell | July 2026

Introduction:

Current antiviral therapies are generally virus-specific and vulnerable to viral mutations. Inspired by the success of mRNA vaccines, this study introduces Viral Protease-Initiated Lytic Cell Death (VIDA)—a novel mRNA platform that selectively destroys virus-infected cells by sensing viral protease activity.

Why was this study needed?

• Most antiviral drugs target a single virus and are susceptible to resistance.
• Broad-spectrum antiviral therapies remain an unmet medical need.
• mRNA technology offers rapid and adaptable therapeutic development.
• Early elimination of infected cells may prevent viral spread.
• AI may accelerate the design of next-generation antiviral therapeutics.

Results:

• VIDA mRNA selectively activated engineered gasdermin proteins only in virus-infected cells, eliminating viral replication while remaining inactive in healthy cells.
• In animal models, VIDA effectively suppressed hepatitis A virus, Zika virus, and SARS-CoV-2, while simultaneously stimulating a protective “kill-and-alert” immune response that enhanced antiviral immunity.
• Artificial intelligence successfully designed optimized viral protease recognition sequences, producing next-generation VIDAs with greater antiviral potency and improved safety.

Clinical Impact:

This study introduces a new paradigm in antiviral therapy. Rather than directly targeting viruses, VIDA targets virus-infected cells, making the approach potentially applicable across multiple viral infections. Combined with mRNA delivery and AI-guided protein engineering, this platform could enable rapid responses to emerging viral outbreaks.

Bottom Line:

VIDA represents a first-in-class universal mRNA antiviral strategy. By combining engineered gasdermins, mRNA technology, and AI-designed viral sensors, it selectively destroys infected cells while activating antiviral immunity, offering a promising platform against current and future viral diseases.